Total Payments
$10,898
2024 Payments
$1,572
Companies
67
Transactions
683
Medicare Patients
3,315
Medicare Billing
$268,185
Payment Breakdown by Category
Food & Beverage$10,689 (98.1%)
Education$113.21 (1.0%)
Other$95.58 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,689 | 676 | 98.1% |
| Education | $113.21 | 2 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $95.58 | 5 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $873.23 | 60 | $0 (2024) |
| GENZYME CORPORATION | $758.99 | 44 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $738.65 | 42 | $0 (2023) |
| UCB, Inc. | $676.88 | 42 | $0 (2024) |
| Biogen, Inc. | $572.60 | 39 | $0 (2024) |
| PFIZER INC. | $526.97 | 43 | $0 (2024) |
| EMD Serono, Inc. | $503.70 | 36 | $0 (2024) |
| Allergan, Inc. | $464.07 | 35 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $426.39 | 25 | $0 (2024) |
| Abbott Laboratories | $395.14 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,572 | 66 | ABBVIE INC. ($434.13) |
| 2023 | $1,005 | 59 | Teva Pharmaceuticals USA, Inc. ($264.18) |
| 2022 | $730.61 | 52 | ABBVIE INC. ($151.65) |
| 2021 | $1,519 | 114 | Biohaven Pharmaceuticals, Inc. ($159.36) |
| 2020 | $1,415 | 96 | Allergan, Inc. ($267.92) |
| 2019 | $1,890 | 107 | GENZYME CORPORATION ($222.53) |
| 2018 | $1,437 | 85 | PFIZER INC. ($229.64) |
| 2017 | $1,329 | 104 | GENZYME CORPORATION ($164.98) |
All Payment Transactions
683 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Neurology | ||||||
| 12/13/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: Neurology | ||||||
| 12/09/2024 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Neurology | ||||||
| 12/06/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $31.85 | General |
| Category: NEUROSCIENCE | ||||||
| 12/05/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: AMANTADINE | ||||||
| 11/21/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: Neurology | ||||||
| 11/07/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2024 | Biogen, Inc. | QALSODY (Drug), SPINRAZA | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Neurology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $5.17 | General |
| Category: Neurology | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $88.21 | General |
| Category: Neuroscience | ||||||
| 10/10/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 10/09/2024 | Chiesi USA, Inc. | CLEVIPREX (Drug) | Food and Beverage | Cash or cash equivalent | $22.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $7.94 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.29 | General |
| 10/02/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Neurology | ||||||
| 10/01/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $16.72 | General |
| Category: NEUROLOGY | ||||||
| 09/27/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: NEUROSCIENCE | ||||||
| 09/26/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 09/12/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Immune | ||||||
| 09/12/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: EPILEPSY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 730 | 913 | $161,884 | $60,172 |
| 2022 | 13 | 743 | 1,004 | $159,331 | $57,302 |
| 2021 | 14 | 939 | 1,299 | $202,899 | $73,599 |
| 2020 | 13 | 903 | 1,228 | $206,101 | $77,112 |
Total Patients
3,315
Total Services
4,444
Medicare Billing
$268,185
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 177 | 202 | $22,157 | $11,728 | 52.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 114 | 138 | $22,994 | $11,528 | 50.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 84 | 143 | $20,420 | $8,014 | 39.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 86 | 88 | $24,256 | $7,989 | 32.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 76 | 142 | $13,699 | $5,053 | 36.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 41 | $14,789 | $4,690 | 31.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $10,051 | $4,033 | 40.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 23 | $4,974 | $1,824 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 17 | 17 | $4,777 | $1,539 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 14 | 18 | $3,042 | $1,196 | 39.3% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 21 | 21 | $9,701 | $843.78 | 8.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 18 | 18 | $6,768 | $642.88 | 9.5% |
| 99283 | Emergency department visit with low level of medical decision making | Facility | 2023 | 12 | 12 | $3,154 | $632.54 | 20.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 14 | $1,102 | $459.50 | 41.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 222 | 300 | $31,800 | $16,159 | 50.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 101 | 106 | $28,090 | $9,791 | 34.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 102 | 237 | $21,804 | $6,261 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 63 | $10,143 | $5,069 | 50.0% |
| 99219 | Initial hospital observation care per day, typically 50 minutes | Facility | 2022 | 52 | 52 | $11,076 | $4,633 | 41.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 54 | 85 | $11,730 | $4,184 | 35.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $9,112 | $3,606 | 39.6% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $5,920 | $2,554 | 43.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $4,260 | $1,544 | 36.3% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 31 | 31 | $13,671 | $1,197 | 8.8% |
| 99224 | Follow-up observation care per day, typically 15 minutes | Facility | 2022 | 29 | 34 | $2,312 | $920.95 | 39.8% |
About Dr. Philip Kurle, MD
Dr. Philip Kurle, MD is a Neurology healthcare provider based in Osage Beach, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184692568.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Kurle, MD has received a total of $10,898 in payments from pharmaceutical and medical device companies, with $1,572 received in 2024. These payments were reported across 683 transactions from 67 companies. The most common payment nature is "Food and Beverage" ($10,689).
As a Medicare-enrolled provider, Kurle has provided services to 3,315 Medicare beneficiaries, totaling 4,444 services with total Medicare billing of $268,185. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Osage Beach, MO
- Active Since 03/10/2006
- Last Updated 07/13/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1184692568
Products in Payments
- UBRELVY (Drug) $744.97
- Briviact (Drug) $627.39
- AUBAGIO (Drug) $417.21
- LYRICA (Drug) $395.64
- APTIOM (Drug) $387.13
- KESIMPTA (Drug) $344.33
- BOTOX (Biological) $321.84
- NUPLAZID (Drug) $306.05
- LEMTRADA (Drug) $290.74
- INFINITY (Device) $262.98
- Aimovig (Biological) $232.37
- AUSTEDO (Drug) $221.21
- EMGALITY (Drug) $220.48
- TECFIDERA (Drug) $203.66
- Mavenclad (Biological) $198.02
- OXTELLAR XR (Drug) $189.90
- NURTEC ODT (Drug) $173.47
- CLEVIPREX (Drug) $173.43
- TROKENDI XR (Drug) $171.68
- Mavenclad (Drug) $163.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.